Law Firms Press Medpace Investors to Seek Lead Role Before Early‑June Securities Class Action Deadline

Overview

• Several investor law firms, in notices Wednesday and Thursday, urged Medpace shareholders to move for lead‑plaintiff status by early June, with deadlines cited as June 5 or June 8.
• The case, pending in the Southern District of Ohio as Durbin v. Medpace Holdings Inc., No. 1:26‑cv‑00346, alleges false statements about cancellation trends and covers April 22, 2025 through February 9, 2026.
• Medpace reported on February 9, 2026 that its 4Q 2025 book‑to‑bill fell to 1.04 due to elevated cancellations, and the stock dropped nearly 16% the next day; book‑to‑bill tracks new contract wins versus billed work and is a key growth gauge for contract research firms.
• Plaintiff counsel say they are probing reports that cancellations worsened in 1Q 2026 with book‑to‑bill near 0.88, alongside the president’s stated plan to resign, which coincided with about a 23% intraday slide on April 23, 2026.
• Firms note that investors may seek to lead the case without paying upfront legal fees because representation is offered on a contingency basis and no class has been certified yet.